Navigation Links
Aktiv-Dry Awarded Research Grant to Explore Inhalable siRNA Dry Powder Targeting RSV
Date:11/12/2007

BOULDER, Colo., Nov. 12 /PRNewswire/ -- Aktiv-Dry LLC has been awarded an SBIR research grant from the Center for Disease Control and Prevention (CDC) to explore the formulation of certain siRNA products as inhalable dry powders that might eventually be used to treat pulmonary disorders such as RSV. Brian Quinn, Ph.D., from Aktiv-Dry, is the principal investigator.

As an intervention strategy for viral infection, new approaches for treating RSV include delivering to the respiratory system short interfering ribonucleic acid oligonucleotides (siRNAs), the molecules that induce RNA interference. Quinn will use Aktiv-Dry's proprietary supercritical carbon dioxide process, CAN-BD, to formulate an oligonucleotide as a powder consisting of micro-scale particles capable of deposition in the lungs.

"The best way to treat an illness is to get the medicine to the principal site of infection, which in the case of RSV is in the lungs," said Quinn, president of Aktiv-Dry. "This proof-of-concept project will attempt to reformulate a siRNA product as a stable, dry powder consisting of particles 1 to 5 microns in diameter. When manufactured under pharmaceutical conditions, infants and children could inhale such particles into their respiratory tracts through the aid of an active dry powder inhaler."

Respiratory syncytial virus (RSV) infects essentially all children within the first two years of life and is the most common cause of bronchiolitis and pneumonia among infants and children under one year of age. It is also a significant cause of morbidity and mortality in the elderly. Each year, RSV infections lead to more than 100,000 hospitalizations and about 2,500 deaths. Current treatment for RSV generally consists of only treating its symptoms, which include fever, runny nose, cough, and sometimes wheezing. No effective drug for treating the RSV infection itself is widely available, nor is there an approved vaccine to prevent RSV.

"If our research is successful, it could lead to a highly effective and noninvasive method for treating RSV and other pulmonary diseases, and provide a tremendous value to the world of public health," said Quinn.

About Aktiv-Dry LLC

Aktiv-Dry LLC, founded in 2002, provides dry powder processing solutions for the vaccine, pharmaceutical, and biotechnology industries. The company is the recipient of a $20 million Grand Challenges in Global Health grant funded through the Foundation for the National Institutes of Health. It has also received government-sponsored R&D grants from the USDA, CDC, and NIH, and undertakes commercial contract research on behalf of biotech and pharmaceutical companies. In addition to its research involving an inhalable measles vaccine, Aktiv-Dry is also involved in research on an inhalable vaccine to help stop smoking and on a project to decrease the body's adsorption of cholesterol that is ingested from food. Other current research projects include the production of dry powders consisting of micro- and nano-particles of oligonucleotides intended for long-term storage. For more information, contact 303-350-3060, and visit the Web site at http://www.aktiv-dry.com.


'/>"/>
SOURCE Aktiv-Dry LLC
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. GeneNews CSO Dr. CC Liew awarded state honour by the Government of Malaysia
2. Mirus Bio Awarded Grants & Contracts of Over $5 Million
3. ICx Awarded $1.5 M Contract by Department of Homeland Security for Development of Next Generation Bio Aerosol Systems
4. ViPS Awarded Enterprise Systems Development (ESD) Contract By CMS
5. GlaxoSmithKline Awarded U.S. Department of Defense Contract to Pursue Novel Antibacterial Research Program
6. Isis Announces $4.2 Million in Government Contracts Awarded to Its Ibis Subsidiary for Biodefense Applications Development
7. Foundation for Biomedical Research Board Chairman Awarded Congressional Gold Medal
8. Isis Awarded $1.5 Million NIH Grant to Improve Chemical Properties of RNAi-Based Therapeutics
9. Caliper Life Sciences Awarded National Institute of Environmental Health Services Contract Valued to $7.0 Million
10. Implicit Awarded US $16.3 Million U.S. Government Contract to Develop Immunomodulatory Drug for Biodefense Threats
11. BIO-key(R) Awarded Contract to Deploy Incident Reporting System for Littleton, CO Police Department
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... 5, 2016 Australian-US drug discovery and development company, ... appointment of a new Chairman, Mr John O,Connor , ... immediately. James Garner , has also been ... former Acting CEO, Mr Iain Ross , will resume ... --> James Garner , has also been formally appointed ...
(Date:2/4/2016)... , February 4, 2016 - New FDA action ... - New FDA action date of July 22, ... July 22, 2016   - ... in the past decade indicated for the treatment of signs and symptoms of ... has the potential to be the only product approved in the U.S. in ...
(Date:2/4/2016)... ... February 04, 2016 , ... Shimadzu Scientific Instruments ... host live demos and poster sessions, and present on the analysis of mycotoxins ... place March 6 to 10 at the Georgia World Congress Center in Atlanta, ...
(Date:2/4/2016)... -- Beike Biotechnology, the Shenzhen ... in late 2015 to mark their successful combined efforts ... --> --> The signing, ... Therapy" was hosted by the Shenzhen Cell Bank and ... Beike Biotechnology Co., Ltd. Shenzhen,s ...
Breaking Biology Technology:
(Date:2/2/2016)... , Feb. 2, 2016 This ... the bioinformatic market by reviewing the recent advances ... tools that drive the field forward. Includes forecast ... Identify the challenges and opportunities that exist ... and software solution developers, as well as IT ...
(Date:2/1/2016)... -- Rising sales of consumer electronics coupled ... gesture control market size through ... electronics coupled with new technological advancements to drive global ... through 2020   --> Rising ... to drive global touchfree intuitive gesture control market ...
(Date:1/25/2016)... 2016   Unisys Corporation (NYSE: UIS ) today ... (JFK) International Airport, New York City , to ... attempting to enter the United States using ... pilot testing of the system at Dulles last year. ... JFK during January 2016. --> pilot testing of ...
Breaking Biology News(10 mins):